MBK Healthcare Management Pte Ltd (“MHM”), a wholly owned subsidiary of Mitsui & Co., Ltd. (“Mitsui”) has supported Mitsui’s participation as the lead investor in a Series B round of Koios Medical, Inc. (“Koios”), a United States based health technology and digital medicine company. MHM will continue to support Mitsui through managing this investment.

 

Koios develops AI-powered clinical decision support software for radiologists, endocrinologists, other trained physicians and technicians, with regulatory clearances from USFDA and CE Marks. Their vendor agnostic solutions can be integrated into most PACS workstations for breast and thyroid ultrasound analysis and reporting. Koios’s software aims to empower physicians in their decision-making process, and enhance the patient experience, catch cancers earlier and reduce unnecessary procedures and the stress associated with false positive findings.

 

AI-enabled decision support solutions such as Koios’s are increasingly important to alleviate the rising pressures in radiology and healthcare systems worldwide brought on by ageing populations, escalating healthcare costs and a healthcare workforce shortage.

 

Koios’s focus on improving both the physician’s and the individual’s experience aligns this investment with Mitsui & MHM’s goal of transforming patient care. MHM aims to facilitate collaborations between Mitsui’s existing portfolio companies and Koios, as well as help Koios expand their presence globally to enable better care for patients.

 

MHM was established in 2016 as Mitsui’s dedicated healthcare operating platform. As the largest shareholder of IHH Healthcare Berhad (IHH, KLSE: 5225, SGX: Q0F), a leading premium healthcare provider operating 80 hospitals in 10 countries with more than 15,000 licensed beds, MHM’s mission is to create long-term value and to grow the portfolio within the healthcare ecosystem of Mitsui.